ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.